Calidi Biotherapeutics, Inc.
CLDI
$1.59
$0.053.25%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.87% | -18.57% | -35.91% | -36.99% | -32.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.59% | -7.05% | -28.18% | -32.43% | -33.78% |
| Operating Income | 3.59% | 7.05% | 28.18% | 32.43% | 33.78% |
| Income Before Tax | 4.69% | 9.67% | 23.40% | 13.75% | 33.14% |
| Income Tax Expenses | 23.08% | 7.14% | 150.00% | -55.00% | -18.75% |
| Earnings from Continuing Operations | 4.67% | 9.66% | 23.35% | 13.79% | 33.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -42.96% | 137.88% | 1,266.67% | -- | -- |
| Net Income | 4.40% | 10.10% | 24.08% | 14.60% | 33.61% |
| EBIT | 3.59% | 7.05% | 28.18% | 32.43% | 33.78% |
| EBITDA | 4.82% | 9.81% | 35.03% | 38.94% | 41.04% |
| EPS Basic | 82.66% | 86.62% | 87.44% | 89.17% | 84.60% |
| Normalized Basic EPS | 84.59% | 87.96% | 88.46% | 76.80% | 49.92% |
| EPS Diluted | 82.66% | 86.62% | 87.44% | 89.17% | 84.60% |
| Normalized Diluted EPS | 84.59% | 87.96% | 88.46% | 76.80% | 49.92% |
| Average Basic Shares Outstanding | 444.73% | 543.49% | 569.06% | 579.97% | 679.78% |
| Average Diluted Shares Outstanding | 444.73% | 543.49% | 569.06% | 481.42% | 389.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |